

Cellular Biomedicine Group, Inc.
Form 8-K
November 30, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2015

CELLULAR BIOMEDICINE GROUP, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other
Jurisdiction of
Incorporation)

001-36498
(Commission File
Number)

86-1032927
(IRS Employer
Identification No.)

19925 Stevens
Creek Blvd.,
Suite 100
Cupertino,
California 95014
(Address of (Zip
Principal Code)
Executive
Offices)

Registrant's telephone number, including area code: (408) 973-7884

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 20, 2015, Cellular Biomedicine Group, Inc. (the "Company") completed its 2015 annual meeting of stockholders (the "Annual Meeting"). The number of shares of common stock entitled to vote at the Annual Meeting was 11,620,165 shares. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 8,271,566 shares. All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and Wen Tao (Steve) Liu, Nadir Patel and Wei (William) Cao were elected "Class III" directors.

The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

(i) To elect three (3) "Class III" directors, each of whom will be elected for a term of three years, or until the election and qualification of their successors.

Nominee	Shares Voted For	Shares Withheld
Wen Tao (Steve) Liu	7,849,055	422,511
Nadir Patel	7,919,246	352,320
Wei (William) Cao	7,046,621	1,224,945

(ii) To ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.

Shares Voted For	Shares Voted Against	Shares Abstaining
7,895,988	851	374,727

Item 7.01 Regulation FD Disclosure.

On November 23, 2015, Cellular Biomedicine Group, Inc. (the "Company") issued a press release announcing the results of the Annual Meeting. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated November 23, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group, Inc.

Date: November 30, 2015

By: /s/ Bizuo (Tony) Liu
Bizuo (Tony) Liu
Chief Financial Officer